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Abstract The cytosolic form of phosphoenolpyruvate carboxy-
kinase (GTP) (PEPCK) gene is differentially expressed in 
several tissues. A specific set of regulatory elements in the 
promoter are responsible for the control of PEPCK gene 
transcription and, in turn, determine its distinct metabolic role 
in each tissue. DNase I footprinting analysis of the PEPCK 
promoter, using nuclear proteins from tissues which express the 
gene for PEPCK, and transient expression assays in renal cell 
lines have demonstrated that the HNF-1 recognition motif (P2) 
in the PEPCK promoter characterizes kidney-specific expres-
sion. This site is required also for the response to acidosis. Since 
the P2 site is not involved in the expression of the PEPCK gene 
in the liver, we propose that its critical role in the kidney stems 
from a combination of abundance of HNF-1 together with low 
concentrations of members of the C/EBP family in this tissue. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Gluconeogenesis in the liver and kidney plays an essential 
role in controlling glucose homeostasis in mammals . In hu-
mans hepatic gluconeogenesis is the predominant process 
which provides glucose to the blood while renal gluconeogen-
esis becomes an important factor only during prolonged star-
vation and during acidosis [1]. Thus, because it is differentially 
regulated, the same gluconeogenic pathway seems to play dif-
ferent roles in the liver and kidney. 
Of the three gluconeogenic enzymes, P E P C K catalyzes the 
key and limiting step of gluconeogenesis. The activity of the 
cytosolic form of P E P C K readily changes in response to a 
variety of hormonal and dietary stimuli, as a result of alter-
ations of the transcriptional rate of the PEPCK gene (for a 
recent review, see [2]). Experimental metabolic acidosis in the 
rat selectively induces the renal, and not hepatic, expression of 
the P E P C K gene [3]. Furthermore, while fasting induces 
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P E P C K gene transcription in both liver and kidney, this stim-
ulation can be differentially abolished in the two tissues i.e. by 
glucose in the liver and by alkalosis in the kidney [4]. Thus, 
the differential modulat ion of P E P C K gene expression in the 
liver and kidney is transcriptionally regulated. 
The transcriptional regulation of the rat P E P C K gene has 
been intensively studied (reviewed in ref. [5]). This single copy 
gene [6], is selectively expressed in several tissues arising from 
different embryonic origins: the liver (endoderm), kidney (in-
termediate mesoderm), and adipose tissue (dorsal mesoderm). 
Using cell lines and transgenic mice, the cw-regulatory regions 
involved in this selective pattern of expression was analyzed 
[7-11]. These analyses have shown that each of the PEPCK-
expressing tissues utilizes distinct regulatory sequences to di-
rect expression of the gene. 
Transcription of the P E P C K gene is modulated by a num-
ber of hormones and other factors in a tissue specific manner. 
Detailed studies in hepatoma cells have led to the identifica-
tion of distinct hormone response elements in the P E P C K 
promoter [12-14]. It is conceivable that the cw-elements which 
determine basal transcription in the liver and kidney also con-
tribute to the tissue-specific modulat ion of the gene in the two 
tissues. 
Here we show by transient transfection experiments with 
cultured kidney cell lines that the HNF-1 recognition motif 
in the P E P C K promoter (P2) plays a dominant role in the 
kidney in both the basal expression of the gene and in its 
response to acidic pH . 
2. Materials and methods 
2.1. Materials 
Dulbecco Modified Eagle's medium (DMEM), F12 and fetal calf 
serum were purchased from Biological Industries, Kibutz Beit Hae-
mek. Quantification of radioactive signals was performed using a 
phosphorimager (Fujix BAS 1000, Fuji, Japan). 
2.2. Cell culture studies 
The proximal tubule cell line from porcine kidney LLC-PK1 (PK1) 
cells (passage 163 obtained from Dr. A. Moran) was grown as pre-
viously described [9], except that the growth medium contained a 1:1 
mixture of DMEM and F12, and 10% fetal calf serum. The same 
medium, but free of glucose, was used for the selection of the PK22 
sub-line of cells enriched in PEPCK activity. The glucose-free selec-
tion medium contained 10 mM pyruvate and 10% dialyzed fetal calf 
serum (containing less than 30 uM glucose) [15]. PK1F+ was a 
PEPCK-enriched sub-line selected by Dr. G. Gstraunthaler, from pa-
rental PK1 cells of passage 280, that was kindly provided to us by Dr. 
Norman P. Curthoys. 
In experiments involving the effect of acidic pH, the cells were 
grown in 25 cm2 Falcon T flasks, which were sealed with a screw 
cap after adjusting the pH by C0 2 aeration. The standardized timing 
of the aeration enabled us to achieve either pH 7.4 or pH 6.9, which 
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was kept constant for the entire 16 h period of the experiment. The 
cultured medium used in these experiments contained 29 mM H C O 3 , 
previously shown to be optimal for the pH effect [16]. 
2.3. Transfection conditions and CAT assays 
Cells were transfected by calcium phosphate precipitation, essen-
tially according to Chen and Okayama [17], as previously described 
[18], using 5 ug of each supercoiled plasmid and additional carrier 
pBS DNA (Stratagene), to make a total of 20 ug. The transfection 
efficiency was monitored by including as an internal standard 0.1 ug 
of pS16-GH [19], containing the human somatotropin (hGH) gene 
driven by the ribosomal protein S16 (rpS16) promoter. The levels of 
hGH secreted into the medium were determined by radio-immune 
assay [19], using a commercial kit (St. Nichols, San Diego, CA) ac-
cording to the supplier's instructions. For experiments involving the 
effect of acidosis, the hGH reporter gene was driven by the Rous 
Sarcoma virus (RSV) promoter/enhancer, rather than by the rpS16 
promoter. Where indicated, 5 (Xg of either HNF- la or HNF-1 fS ex-
pression vectors were added to the transfection mix. The calcium-
phosphate-DNA precipitates were left on the cells for 5 h. After their 
removal, the cells were rinsed and shocked for 1.5 min. with 20% 
glycerol. The transfected cells were harvested after two days and the 
activity of the chloramphenicol acetyltransferase (CAT) reporter was 
determined as previously described [18]. The percent of acetylated 14C 
labeled chloramphenicol, from the sum of acetylated and non-acetyl-
ated spots identified by autoradiography of the TLC plates, was quan-
tified using a phosphorimager apparatus. CAT activity was normal-
ized to the amount of hGH secreted into the medium as previously 
described [18]. 
2.4. PEPCK activity assay 
Activity was determined in the post-mitochondrial supernatant of 
the cells, using a 14CC"2 fixation assay [20]. One unit of enzyme activ-
ity catalyzes the fixation of 1 umol of NaH14CC>3 per minute at 37°C. 
2.5. Plasmids used in transfection 
pSV2-cat is a plasmid containing the structural gene encoding the 
bacterial chloramphenicol acetyltransferase (CAT) gene fused to the 
simian virus 40 (SV40) early promoter-enhancer region in pBR322 
[21]. The previously described plasmid 597-pck-CAT, has 597 bp of 
the PEPCK promoter region fused to the CAT reporter gene [7]. The 
derived plasmid A362-205-pck-CAT (AP3,P4) contains an internal de-
letion in the PEPCK promoter, spanning positions —362 to —205 of 
the transcription start site [7], which has two C/EBP recognition se-
quences [22,23]. Plasmid A487-417-pck-CAT (AP6) also derives from 
597-pck-CAT and contains an internal deletion between positions 
—487 to —417 of the transcription start site [9] which has an AF1 
site, the HNF-4 recognition sequence [22,24]. Plasmid mh-597-pck-
CAT (mP2), where the P2 binding site (an HNF-1 motif [25]) in the 
sequence spanning positions —155 to —205 of plasmid 597-pck-CAT 
was replaced by 50 bp of a polylinker sequence from the commercial 
plasmid pBlueScript (Stratagene), has been previously described [18]. 
PEPCK-CAT containing plasmids, where the PI and CRE sites in the 
PEPCK promoter were mutated (mPl and mCRE, respectively), and 
the plasmid containing the unmodified PEPCK promoter (—460 to 
+73) were described previously [13]. Expression vectors encoding hep-
atic enriched transcription factors used in this work included: HNF-
l a (also termed HNF-1) [26] and HNF-lp1 (also termed vHNF-1) [27]. 
2.6. DNase Ifootprinting assays 
Nuclear extracts from rat liver and kidney were prepared by a 
modification [22] of the method of Gorski et al. [28]. Nuclear extracts 
from cultured adipocytes were prepared according to Dignam et al. 
[29], with a modification adapted from Gorski et al., where MgC^ 
was replaced by spermine spermidine [28]. DNase I footprinting as-
says were performed essentially as previously described [22] using the 
32P-end labeled probe containing the 610 bp BamHl-Bglll fragment of 
the rat PEPCK promoter, spanning positions —540 to +69 of the 
gene. 
3. Results 
3.1. Analysis of distinct sequences in the PEPCK promoter 
Previous DNase I footprint analysis of the PEPCK pro-







Fig. 1. Footprinting of the PEPCK promoter region with nuclear 
extracts from the kidney, liver and adipocytes. Ten fentomols of 
32P-end labeled 610 bp of BamHI-Bglll fragment encompassing the 
entire rat PEPCK promoter up to position —540 of the gene were 
incubated either with 20 |xg of nuclear proteins extracted from the 
kidney (K), liver (L) and adipocytes (A) or in the absence of pro-
teins (O). After digestion with DNase I the DNA was separated on 
a sequencing gels. The protected sequences are indicated on the 
right. Analysis of sequences upstream of position —362 is not 
shown. 
moter compared the binding by nuclear extracts from tissues 
that express PEPCK (liver and kidney) to extracts from non-
expressing tissues (spleen and brain) [25]. This comparative 
analysis readily identified sequences that specifically bind hep-
atic nuclear proteins, later identified as C/EBP binding sites 
[22,23]. In contrast, the pattern of binding to the PEPCK 
promoter of proteins extracted from renal nuclei did not differ 
from footprints obtained with nuclear extracts from tissues 
which do not express the gene for PEPCK. To verify the 
sequences within the PEPCK promoter which differentially 
bind renal nuclear proteins, footprint analysis of nuclear ex-
tracts from the three PEPCK-expressing tissues, kidney, liver 
and adipocytes was performed (Fig. 1). Hepatic nuclear pro-
teins footprinted all sites. These included the tissue-non-spe-
cific CRE site (cAMP response element) which binds CREB, 
API and C/EBP, the PI site which binds nuclear factor 1 
(NF1), and the tissue-specific sites including P2, which binds 
hepatic nuclear factor 1 (HNF-1), and P3 and P4 which bind 
members of the C/EBP family (for reviews, see [2,30]). 
All except one of these sites were bound by nuclear proteins 
from adipocytes. The only site in the PEPCK promoter which 
failed to bind nuclear proteins from adipocytes was the P2 
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Fig. 2. Analysis of sequences in the PEPCK promoter region which 
regulate its transcription in several lines of kidney cells. The figures 
represent CAT activities driven by the native PEPCK promoter (wt) 
and by the following mutants: A487-417-pck-CAT (AP6) [9] which 
contains an internal deletion of the HNF-4 recognition site; A362-
205-pck-CAT (AP3,P4) which contains an internal deletion of two 
C/EBP recognition sequences [7]; mh-597-pck-CAT (mP2), where 
the HNF-1 recognition sequence has been replaced by a non-rele-
vant poly linker [18]; mPl, where the PI element was mutated and 
mCRE, where the CRE element was mutated [13]. CAT activity 
was determined using phosphorimager, calibrated according to the 
amount of hGH secreted, and expressed as percent of the unmodi-
fied PEPCK promoter activity. Most values are the average of two 
independent transfection experiments except for the P2 mutant 
(mP2) and the CRE mutant (mCRE) which are the averages ± S.E. 
of eight and three independent transfection experiments, respec-
tively. 
site, which is known to bind HNF-1. Because this site was 
efficiently footprinted by nuclear proteins from the PEPCK-
non expressing spleen [22,25], and considering the expression 
of vHNF-1 (HNF-1 p) in many tissues including the spleen 
[27], the adipocytes appear to lack HNF-1. 
In contrast to the liver and adipocytes, the kidney nuclear 
proteins footprinted only two of the sites, PI and P2. Strik-
ingly, the kidney proteins not only failed to bind the bona fide 
C/EBP recognition P3 and P4 sites but, also failed to bind the 
CRE site, which is not involved in determining the tissue 
specific expression of the PEPCK gene. Binding of kidney 
nuclear proteins was limited to PI, which contains the ubiq-
uitous NF-1 motif and P2, containing the HNF-1 motif (Fig. 
1). We also observed binding of renal proteins to the P6 site 
of the PEPCK promoter (data not shown), which is known to 
bind members of the super family of nuclear receptors [31,32]. 
Thus, the binding of renal nuclear proteins was considerably 
restricted compared to those obtained by nuclear proteins 
from the other two PEPCK-expressing tissues and notwith-
standing the comparable levels of PEPCK gene expression in 
the three tissues. 
3.2. Basal PEPCK promoter activity in kidney cell lines 
Transient transfection experiments were employed to ana-
lyze the role of the distinct recognition sites of the PEPCK 
promoter in conferring its renal expression. To this end, we 
used LLC-PK1 porcine kidney cells (PK1) which weakly ex-
press the PEPCK gene (17 ± 6 milliunits per mg protein) and 
two derivative sub-cell lines, enriched for this expression, that 
have been obtained by selecting PK1 cells in glucose-free me-
dium in the presence of 10 mM pyruvate. These included 
PK22 cells which express the gene 3 times higher than PK1 
(52 ± 6 milliunits/mg protein) and PK1F+, containing 15 times 
higher PEPCK activity (260 ±15). These enzymatic activities 
were in accord with the activities of the PEPCK promoter in 
these cells determined by transient transfection of the cells 
with 597-pck-CAT plasmid containing the PEPCK promoter 
driving the reporter CAT gene [7]. Thus, relative to the activ-
ity of the SV40 early promoter/enhancer (pSV2-cat [21]), 
PEPCK promoter activity was 1.4 ±0.20 in PK1 cells; 
4.1 ± 1.4 in PK22 cells and 9.0 ±2.3 in PK1F+ cells. 
The functional roles of the recognition sequences of the 
PEPCK promoter have been assessed using distinct mutants 
including: (a) deletion of the sequence containing the HNF-4 
recognition sequence (P6) in the plasmid A487-417-pck-CAT 
(AP6), and deletion of the C/EBP recognition sequences P3 
and P4 in the plasmid A362-205-pck-CAT (AP3,P4) [7,9]; (b) 
replacement of the HNF-1 recognition sequence P2 by a non-
relevant sequence in the plasmid mh-597-pck-CAT (mP2) 
[18]; and (c) mutations of the PI and CRE sites in the plas-
mids mPl and mCRE [13]. 
The analyses revealed (see Fig. 2) that replacement of the 
HNF-1 recognition motif (mP2) markedly reduced PEPCK 
promoter activity in all three cell lines tested. The importance 
of this sequence for basal promoter activity was further accen-
tuated by the lack of significant effects of deleting or mutating 
other sites in the PEPCK promoter. Deletion of the P3, P4 
and P6 sites and mutation of the CRE site resulted in a 
slightly elevated activity, while mutation of the PI site resulted 
in a slightly reduced activity of the PEPCK promoter (Fig. 2). 
We have previously reported that deletion of the sequence 
spanning positions —205 to —98 of the PEPCK promoter, 
which contained both the P2 and PI sites, completely abol-
ished its activity in PK1 cells [9]. Our present data suggests 
that the P2 element may play a more significant role than PI 
PK1 PK22 
Fig. 3. Transactivation of the PEPCK promoter in sub-lines of kid-
ney cultured cells by HNF-la. Cultured kidney cells were trans-
fected with 597-pck-CAT (wt) or with the P2 mutant (mP2) alone, 
or co-transfected with HNF-la expression vector. CAT activities 
were quantified using the phosphorimager and calibrated according 
to the amount of hGH secreted. The activity of the unmodified 
PEPCK promoter in each cell line, when transfected alone, was 
used to normalize the activity of the mutant (mP2) and the fold 
stimulation of the wild type and mutant PEPCK promoter by the 
co-transfected expression vector coding for HNF-la. The histogram 
represents the average fold stimulation in the presence of the tran-
scription factor, for 6 independent experiments. The S.E. of the 
mean is indicated by the vertical bars. 
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Fig. 4. Effect of acidic pH on transcription from the PEPCK pro-
moter in PK22 cells: PK22 cells were transfected with 597-pck-CAT 
(wt) or with various derivative mutants indicated in the x-axis and 
described in the legend to Fig. 2. The transfection medium included 
RSV-hGH plasmid as an internal control. Twenty-four hours after 
transfection, the medium was replaced with either a medium at pH 
7.4 or pH 6.9 for 16 h. CAT activity was determined using the 
phosphorimager, calibrated according to the amount of hGH se-
creted, and expressed relative to the unmodified PEPCK promoter 
activity at pH 7.4. The bargraphs represent the mean fold stimula-
tion by acidic pH of CAT activity resulting from the wild type con-
struct (2.5 ± 0.3 [S.E.M.] of 3 independent transfection experiments) 
and from the various mutant constructs (the means of two transfec-
tion experiments). However, the liver-specific P6 and P3 elements 
may also play a role in the expression of the PEPCK gene in the 
kidney, since their removal increases transcription from the PEPCK 
promoter in kidney cells (as can be seen here in Fig. 2) and in 
transgenic mice, where deletion of the P6 domain and mutation of 
the C/EBP recognition site (P3) result in an increased renal expres-
sion of the transgenes [11,34]. Recently, the disruption of the gene 
for C/EBPa has been shown to result in postnatal lethality with hy-
poglycemia and absence of hepatic PEPCK in the homozygous mu-
tant mice [35], thus, corroborating the important role of this tran-
scription factor for hepatic expression of the PEPCK gene. In 
contrast, the renal expression of the PEPCK gene in these mice has 
increased several fold over the normal level (Croniger, Darlington 
and Hanson, unpublished results). Thus, despite its low level in the 
kidney, C/EBPa might interact via the P3 element with some other 
factor to restrain the renal transcription of the PEPCK gene. We 
have recently shown in hepatoma cells, that members of the C/EBP 
family interact with HNF-1 a via their respective recognition motifs 
in the PEPCK promoter to stimulate transcription from this pro-
moter [18]. It is tempting to speculate that such interaction in kid-
ney cells will restrain, rather than stimulate, the renal transcription 
of the PEPCK gene. 
in the PEPCK promoter activity in kidney cells (Fig. 2). The 
dominant role of the P2 observed here in all three kidney cell 
lines, is in striking contrast to its failure to affect the promoter 
activity in hepatoma cells [13]. We have previously shown, 
however, that P2 could become important in hepatoma cells 
when the promoter activity was stimulated by co-transfection 
of HNF-1 a together with members from the C/EBP family 
[18]. 
In view of the dominant role played by the P2 site in all 
three kidney cell lines it was conceivable that members of the 
HNF-1 family by themselves could stimulate the promoter 
activity in these cells. Indeed, when HNF- la was co-trans-
fected with the 597-pck-CAT plasmid the PEPCK promoter 
activity was stimulated 5 to 4 fold in PK1 and PK22 cells 
(Fig. 3). The trans-activation of the PEPCK promoter by 
HNF- la was dependent on the presence of its cognate recog-
nition motif in the promoter. Likewise, HNF-1 P stimulated 
the promoter activity when co-transfected together with 597-
pck-CAT (data not shown). It should be noted that the liver 
expresses only HNF- la while the kidney expresses both 
HNF- la and HNF-lp [27,33]. 
3.3. Modulation of the PEPCK promoter activity by acidic pH 
As mentioned above the activity of the PEPCK gene can be 
modulated by external conditions such as pH. To determine 
whether the presence of an intact P2 was also required for the 
modulation of the PEPCK promoter activity by acidic pH, 
PK22 cells were transfected with 597-pck-CAT and 24 h later 
the cell culture medium was replaced by a medium containing 
29 mM HCO3 at either pH 7.4 or pH 6.9 for 16 h (see 
Methods in Section 2). These experimental conditions have 
been used previously to demonstrate a maximal response of 
the endogenous PEPCK gene to acidic pH in PK1F+ cells 
[16]. We noted that the acidic pH stimulated the PEPCK 
promoter by 2.5 ± 0.3 fold (the mean ± S.E. of three independ-
ent transfection experiments). The stimulation of CAT activity 
by acidic pH was also observed with mutated promoters, in-
cluding mutations in the CRE, PI, P2 or P3/P4 sites. How-
ever, the extent of the stimulation was considerably lower 
when the P2 element (the HNF-1 motif) was mutated (Fig. 
4) albeit, the basal activity with the mutated P2 was low. 
4. Discussion 
In this report we demonstrate that the renal expression of 
the gene for PEPCK specifically depends on a single regula-
tory element in the promoter that contains the HNF-1 motif 
(P2). This element appears to play a dominant role in both the 
basal and acidosis-stimulated activity of the promoter. 
Previous studies with transgenic mice have shown that dif-
ferent elements are required for PEPCK gene expression in 
the liver, kidney and adipose tissue [8,10,11]. For example, the 
CRC362 transgene, which lacks the P6 element, is not ex-
pressed in the liver while it is fully expressed in the kidney 
[11] and fully responds to metabolic acidosis (Olswang and 
Reshef, unpublished results). The P6 element is important in 
cultured H4IIEC3 hepatoma cells [7,9] but not in cultured 
LLC-PK1 kidney cells ([9] and present work). 
Further studies using transgenic mice [34] have recently 
shown that the C/EBP binding element, P3, is required for 
full expression of the PEPCK gene in the liver but not in 
the kidney. Likewise, this element is not required for PEPCK 
promoter activity in cultured kidney cells as shown in the 
present work. In contrast, the HNF-1 recognition domain is 
required for renal expression of the PEPCK gene. Thus, mu-
tation of this recognition motif (P2) markedly reduces the 
transgene expression in the kidney but not in the liver [34]. 
Similarly, as shown here, mutation of the HNF-1 recognition 
motif (P2) in the PEPCK promoter markedly reduces its ac-
tivity in cultured kidney cells regardless of whether the pro-
moter activity is low (PK1 cells) or high (PK1F+ cells). Taken 
together, these studies establish the differential roles of dis-
tinct sequences of the PEPCK gene in the regulation of its 
specific transcription in the liver and kidney. While at least 
two elements (the P6 and P3 sites) are required for full hepatic 
expression, a dominant single element, the HNF-1 recognition 
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motif (P2), appears to be critical for the renal-specific expres-
sion of the PEPCK gene. 
In view of the high level of HNF- la in both the liver and 
kidney it is, however, not clear why the P2 binding site of the 
PEPCK promoter is critically required for the renal expres-
sion of the PEPCK gene, while it is not required for expres-
sion in the liver. This issue is further emphasized by the dis-
ruption of the gene for HNF- la in mice, which leads to 
lethality around the time of weaning. These mice develop 
renal Fanconi syndrome and fail to tolerate overnight fasting 
[33]. In contrast, hepatic PEPCK gene expression is normal in 
these mutant mice indicating its independence of HNF-la. 
This differs from the expression of several other liver-specific 
genes that was affected by this mutation in the liver. In par-
ticular, the absence of expression of phenylalanine hydroxyl-
ase (4-monooxygenase), resulting in phenylketonuria [33]. 
Unlike the hepatic expression of the PEPCK gene, which is 
induced by birth, the renal expression is notably negligible 
during the first post-natal days [11] and attains adult levels 
only toward weaning (Olswang and Reshef, unpublished re-
sults). It would be interesting to find out whether renal 
PEPCK gene expression is affected in the HNF- la mutant 
mice at weaning, when the mutation becomes lethal. 
In addition to basal PEPCK gene transcription, we have 
now shown that the P2 sequence is required in cultured kidney 
cells for a full response of the PEPCK promoter activity to 
acidic pH. However, P2 itself is unlikely an acidosis response 
element because of the partial response of the P2 mutant to 
this treatment. Moreover, P2 seems to be necessary for mod-
ulation of the promoter activity by other treatments as well. 
Thus, in preliminary experiments we have recently observed a 
marked stimulation of the promoter activity in PK1 cells by 
the peroxisome proliferator-activated receptor (PPARa), 
whose recognition site in the promoter was previously as-
signed to P6 [32]. This trans-activation was considerably re-
duced when using the mP2 plasmid, containing a mutated P2 
site (Heineman, Olswang and Reshef, to be published else-
where). Since P2 does not bind PPAR, it most conceivably 
cooperates with sites which bind PPAR [32]. Cooperation 
between a bona-fide cell-specific element with elements medi-
ating the gene response to various stimuli has been repeatedly 
shown. Thus, the response of the PEPCK gene to glucocorti-
coids requires cooperation between several elements, including 
P6 which is not a glucocorticoid receptor binding site [12], and 
its response to cAMP requires cooperation of the CRE with 
the cell-specific P3 element (a C/EBP motif) [13]. Such coop-
eration has been shown also in the cases of the tyrosine ami-
no-transferase [36] and phenylalanine hydroxylase genes [37]. 
The involvement of P2 in more than one type of modulation 
of the PEPCK gene in the kidney cells is striking. This is even 
more emphasized in view of its dispensable role in the liver. It 
is tempting to speculate that the favored dominant role of P2 
in the kidney is attained because the kidney nuclei are poor in 
proteins that bind to P3 and CRE sites, as evident by the lack 
of their footprinting by kidney nuclear proteins. Thus, we 
propose that the dominant role of P2 in the kidney not only 
reflects high levels of HNF-la, but also the low levels of C/ 
EBP in the kidney. This hypothesis, which is currently under 
investigation, also predicts that P2 will not play such an im-
portant role in adipocytes not only because adipocytes are 
poor in proteins that bind the P2 site but also because they 
abundantly express members from the C/EBP family. 
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